ORIGINAL RESEARCH
Cell and Organ Transplantology. 2026; 14(1):e2026141193.
DOI: 10.22494/cot.v14-1.193
Comprehensive characterization of human Wharton’s jelly mesenchymal stromal cells isolated by the combined explant-enzymatic method
Obushko R.1
, Trufanova N.1
, Revenko O.1
, Cherkashina D.1
, Lipko O.2,3
, Zubov P.1
, Petrenko O.1![]()
- 1Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine
- 2Kharkiv National Medical University, Kharkiv, Ukraine
- 3Municipal non-commercial enterprise “City Clinical Hospital No. 27” of the Kharkiv City Council, Kharkiv, Ukraine
Abstract
Human mesenchymal stromal cells (MSCs) derived from Wharton’s jelly (WJ) are a premier source for regenerative medicine. However, standardized isolation protocols that ensure both high cell yield and maintained proliferative potential remain a subject of active research.
This study is aimed to evaluate the efficiency of a combined explant-enzymatic method for human WJ-MSC isolation and characterize the resulting cell populations.
Materials and methods. Cells were isolated using a combined explant-enzymatic method. Minced WJ fragments were cultured on gelatin-coated surfaces for 7 days, then explants underwent a brief (5–10 min) in situ enzymatic treatment with a trypsin-Versene solution, followed by further co-cultivation of the tissue fragments and released cells for an additional 7 days prior to the first passage. Cell characterization included colony-forming unit (CFU), immunophenotyping (CD29, CD90, CD73, CD105, CD34, CD45), directed differentiation (adipogenic and osteogenic), and secretory activity assays. Proliferative kinetics were assessed by calculating the population doubling time (PDT) across 5 passages. Secretory profile of WJ-MSCs (growth factors and cytokines regulating reparative-regenerative processes) was studied by enzyme-linked immunosorbent assay of conditioned media collected after 48 h cell incubation in minimal culture media.
Results. The combined method ensured a stable cell yield with high reproducibility. Significant inter-donor variability in primary cell yield was noted. Isolated cells fulfilled the ISCT minimal criteria, exhibiting typical fibroblast-like morphology, characteristic immunophenotype, differentiation potential, and a high proportion of CFU, indicating the preservation of primitive progenitors. Proliferative analysis showed that PDT values remained comparable and did not change significantly between passages 1 and 3. Conditioned media from WJ-MSCs contained wide range of growth factors and cytokines, with inter-donor variability: VEGF, EGF, PDGF-BB, SCF, TNF-α, and TGF-β exhibited wide fluctuations, whereas NGF-β and FGF-β were relatively stable. Overall, WJ-MSC CM were characterized by very high levels of VEGF and EGF, high PDGF-BB, elevated TNF-α and TGF-β, and the lowest levels of FGF-β.
Conclusions. The combined explant-enzymatic method is an efficient and standardized protocol for human WJ-MSC isolation, preserving high functional potency of cells for clinical and biobanking purposes.
Keywords: mesenchymal stromal cells; Wharton’s jelly of the umbilical cord; colony-forming activity; immunophenotype; directed differentiation; conditioned medium
Full text PDF
| 1. Torre P, Flores AI. Current status and future prospects of perinatal stem cells. Genes (Basel). 2020; 2(1):6. https://doi.org/10.3390/genes12010006 PMid:33374593 PMCid:PMC7822425 |
||||
| 2. Deus IA, Mano JF, Custódio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020; 110:1-14. https://doi.org/10.1016/j.actbio.2020.04.035 PMid:32418650 |
||||
| 3. El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014; 20(5):523-44. h https://doi.org/10.1089/ten.teb.2013.0664 PMid:24552279 |
||||
| 4. Watson N, Divers R, Kedar R, Mehindru A, Mehindru A, Borlongan MC, et al. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015; 17(1):18-24. https://doi.org/10.1016/j.jcyt.2014.08.009 PMid:25442786 PMCid:PMC4274214 |
||||
| 5. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013; 8(2):144-155. https://doi.org/10.2174/1574888X11308020005 PMid:23279098 |
||||
| 6. Conconi MT, Di Liddo R, Tommasini M, Calore C, Parnigotto PP. Phenotype and Differentiation Potential of Stromal Populations Obtained from Various Zones of Human Umbilical Cord: An Overview. Open Tissue Eng Regen Med J. 2011;4:6-20 https://doi.org/10.2174/1875043501104010006 |
||||
| 7. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, et al. Immunogenicity of umbilical cord tissue-derived cells. Blood. 2008; 111(1):430-438. https://doi.org/10.1182/blood-2007-03-078774 PMid:17909081 |
||||
| 8. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells. 2008; 26(11):2865-74. https://doi.org/10.1634/stemcells.2007-1028 PMid:18703664 |
||||
| 9. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004; 22(7):1330-1337. https://doi.org/10.1634/stemcells.2004-0013 PMid:15579650 |
||||
| 10. Stefańska K, Ożegowska K, Hutchings G, Popis M, Moncrieff L, Dompe C, et al. Human Wharton’s Jelly-cellular specificity, stemness potency, animal models, and current application in human clinical trials. J Clin Med. 2020; 9: 1102. https://doi.org/10.3390/jcm9041102 PMid:32290584 PMCid:PMC7230974 |
||||
| 11. Tsymbalyuk VI, Deryabina OG, Shuvalova NS, Maslova OO, Pokholenko YO, Toporova OK, et al. Phenotypic changes and proliferative potential of mesenchymal stem cells from human umbilical cord Wharton’s jelly under cultivation conditions. Ukr Neurosurg J. 2015; 2:17-24 https://doi.org/10.25305/unj.45290 |
||||
| 12. Hassan G, Kasem I, Soukkarieh C, Aljamali M. A simple method to isolate and expand human umbilical cord derived mesenchymal stem cells: using explant method and umbilical cord blood serum. Int J Stem Cells. 2017; 10:184-92. https://doi.org/10.15283/ijsc17028 PMid:28844128 PMCid:PMC5741200 |
||||
| 13. Zheng S, Gao Y, Chen K, Liu Y, Xia N, Fang F. A robust and highly efficient approach for isolation of mesenchymal stem cells from Wharton’s Jelly for tissue repair. Cell Transplant. 2022; 31:9636897221084354. https://doi.org/10.1177/09636897221084354 PMid:35313748 PMCid:PMC8943591 |
||||
| 14. Tsagias N, Koliakos I, Karagiannis V, Eleftheriadou M, Koliakos GG. Isolation of mesenchymal stem cells using the total length of umbilical cord for transplantation purposes. Transfus Med. 2011; 21:253-61. https://doi.org/10.1111/j.1365-3148.2011.01076.x PMid:21623971 |
||||
| 15. Hua J, Gong J, Meng H, Xu B, Yao L, Qian M, et al. Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow. Cell Biol Int. 2013; https://doi.org/10.1002/cbin.10188 PMid:24123669 |
||||
| 16. Yoon JH, Roh EY, Shin S, Jung NH, Song EY, Chang JY, et al. Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton’s jelly. Biomed Res Int. 2013; 2013:428726. https://doi.org/10.1155/2013/428726 PMid:23653895 PMCid:PMC3638666 |
||||
| 17. Banitalebi Dehkordi M, Madjd Z, Chaleshtori MH, Meshkani R, Nikfarjam L, Kajbafzadeh AM. A Simple, rapid, and efficient method for isolating mesenchymal stem cells from the entire umbilical cord. Cell Transplant. 2016; 25(7):1287-97. https://doi.org/10.3727/096368915X688911 PMid:26270183 |
||||
| 18. Patent No. UA157237. U MPK C12N5/071 C12N5/074 C12N5/095. Method for isolating mesenchymal stem cells from Wharton’s jelly of the umbilical cord connective tissue. Petrenko OY, Trufanova NA, Trufanov OV, Prokopyuk VY., Gubenya OS, Oberemok RA, Revenko OB. Application No. u202401536, filed on 03/25/2024. Published on 09/18/2024. Available from: https://iprop-ua.com/inv/m5qzc6z5/ | ||||
| 19. Nguyen JL, Mohamed-Ahmed S, Saleem R, Mustafa K, Al-Sharabi N, Bentsen MHL. Isolation methods influence the biological properties of Wharton’s jelly-derived mesenchymal stem cells: a comparative study of yield, viability, proliferation, differentiation potential, and proteomic profiles. PLoS One. 2026; 21(3): e0345081. https://doi.org/10.1371/journal.pone.0345081 PMid:41860834 PMCid:PMC13004360 |
||||
| 20. Mennan C, Wright K, Bhattacharjee A, Balain B, Richardson J, Roberts S. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res Int. 2013; 2013:916136. 6 https://doi.org/10.1155/2013/916136 PMid:23984420 PMCid:PMC3741948 |
||||
| 21. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001; 98(8):2396-402. https://doi.org/10.1182/blood.V98.8.2396 PMid:11588036 |
||||
| 22. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13(12):4279-95. https://doi.org/10.1091/mbc.e02-02-0105 PMid:12475952 PMCid:PMC138633 |
||||
| 23. Acuto S, Lo Iacono M, Baiamonte E, Lo Re R, Maggio A, Cavalieri V. An optimized procedure for preparation of conditioned medium from Wharton’s jelly mesenchymal stromal cells isolated from umbilical cord. Front Mol Biosci. 2023; 10:1273814. https://doi.org/10.3389/fmolb.2023.1273814 PMid:37854039 PMCid:PMC10580810 |
||||
| 24. Cherkashina DV, Revenko OB, Rogulska OY, Petrenko OY Destructive and reparative processes in rat’s skin after burn in presence of stem and progenitor cell bioregulators. Probl Cryobiol Cryomed. 2018; 28(1):24-28. https://doi.org/10.15407/cryo28.01.024 |
||||
| 25. Miller GL. Protein determination for large numbers of samples. Anal Chem. 1959; 31(6): 964. https://doi.org/10.1021/ac60149a611 |
||||
| 26. Mahmoud R, Bassiouny M, Badawy A, Darwish A, Yahia S, El-Tantawy N. Maternal and neonatal factors’ effects on Wharton’s jelly mesenchymal stem cell yield. Sci Rep. 2024; 14(1):24376. https://doi.org/10.1038/s41598-024-72386-z PMid:39420012 PMCid:PMC11487262 |
||||
| 27. Marleau AM, Pearl JR, Juarez P, Almeida P, Miguel S, Olvera Felix E, et al. Critical evaluation of compositions and clinical relevance of Wharton’s jelly-derived biologics. J Transl Med. 2026; 24(1):189. https://doi.org/10.1186/s12967-025-07612-x PMid:41580705 PMCid:PMC12903654 |
||||
| 28. Ali H, Al-Yatama MK, Abu-Farha M, Behbehani K, Al Madhoun A. Multi-lineage differentiation of human umbilical cord Wharton’s Jelly Mesenchymal Stromal Cells mediates changes in the expression profile of stemness markers. PLoS One. 2015; 10(4):e0122465. https://doi.org/10.1371/journal.pone.0122465 PMid:25848763 PMCid:PMC4388513 |
||||
| 29. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, et al. Mesenchymal stem cells from the Wharton’s jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion. 2008; 48(12):2638-44. https://doi.org/10.1111/j.1537-2995.2008.01926.x PMid:18798803 PMCid:PMC3444149 |
||||
| 30. Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. In Vitro Cell Dev Biol Anim. 2009; 45(1-2):23-7. https://doi.org/10.1007/s11626-008-9155-4 PMid:19057971 |
||||
| 31. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. https://doi.org/10.1080/14653240600855905 PMid:16923606 |
||||
| 32. Kim H-K, Lee S-G, Lee S-W, Oh BJ, Kim JH, Kim JA, et al. A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells. Stem Cells. 2019; 37:77-88. https://doi.org/10.1002/stem.2920 PMid:30281870 |
||||
| 33. Azis R, Widowati W, Gunanegara RF, Kusuma HSW, Triharsiwi DN, Hadiprasetyo DS, et al. Anti‐inflammatory properties of conditioned medium from human Wharton’s jelly mesenchymal stem cells. Indones. J. Biotechnol. 2025; 30(4):217-225. https://doi.org/10.22146/ijbiotech.107035 |
||||
| 34. Maged G, Abdelsamed MA, Wang H, Lotfy A. The potency of mesenchymal stem/stromal cells: does donor sex matter? Stem Cell Res Ther. 2024; 15(1):112. https://doi.org/10.1186/s13287-024-03722-3 PMid:38644508 PMCid:PMC11034072 |
||||
| 35. Lee SY, Bharti D, Son YB, Lee WJ, Choe YH, Lee HJ, et al. Gender difference of Wharton’s jelly-derived mesenchymal stem cells on differentiation potential into functional granulosa cells. Cell Mol Biol (Noisy-le-grand). 2025; 71(4):22-29. https://doi.org/10.14715/cmb/2025.71.4.3 PMid:40285788 |
||||
| 36. Balzano F, Bellu E, Basoli V, Dei Giudici S, Santaniello S, Cruciani S, et al. Lessons from human umbilical cord: gender differences in stem cells from Wharton’s jelly. Eur J Obstet Gynecol Reprod Biol. 2019; 234:143-148. https://doi.org/10.1016/j.ejogrb.2018.12.028 PMid:30690190 |
||||
Obushko R, Trufanova N, Revenko O, Cherkashina D, Lipko O, Zubov P, Petrenko O. Comprehensive characterization of human Wharton’s jelly mesenchymal stromal cells isolated by the combined explant-enzymatic method. Cell Organ Transpl. 2026; 14(1):e2026141193. doi: https://doi.org/10.22494/cot.v14-1.193

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

